PTPN3 is a potential immune checkpoint inhibitor target that may mediate T cells, while PTPN5 and PTPN7 can specifically inactivate MAPKs, so the developed inhibitors may have therapeutic potential for treating neurodegenerative diseases in AML patients19,20. This evidence concerns the gene PTPN7 and acute myeloid leukemia.